Critical Contrast: Merit Medical Systems (MMSI) vs. Its Peers

Merit Medical Systems (NASDAQ: MMSI) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Merit Medical Systems to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

95.2% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 5.0% of Merit Medical Systems shares are owned by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Merit Medical Systems and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Merit Medical Systems $727.85 million $27.52 million 35.47
Merit Medical Systems Competitors $1.54 billion $111.80 million -145.46

Merit Medical Systems’ rivals have higher revenue and earnings than Merit Medical Systems. Merit Medical Systems is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Merit Medical Systems has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Merit Medical Systems’ rivals have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.


This table compares Merit Medical Systems and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Merit Medical Systems 3.78% 9.65% 6.02%
Merit Medical Systems Competitors -62.26% -47.35% -18.28%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Merit Medical Systems and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems 0 0 11 0 3.00
Merit Medical Systems Competitors 492 1882 3745 115 2.56

Merit Medical Systems currently has a consensus price target of $48.60, suggesting a potential upside of 7.05%. As a group, “Surgical & medical instruments” companies have a potential upside of 9.87%. Given Merit Medical Systems’ rivals higher probable upside, analysts clearly believe Merit Medical Systems has less favorable growth aspects than its rivals.


Merit Medical Systems beats its rivals on 8 of the 13 factors compared.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products focused in four product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, and endoscopy.

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with's FREE daily email newsletter.

Leave a Reply